$0.68
-0.10 (-13.21%)
Open$0.74
Previous Close$0.78
Day High$0.77
Day Low$0.67
52W High$2.93
52W Low$0.70
Volume—
Avg Volume13.31M
Market Cap150.23M
P/E Ratio—
EPS$-0.22
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+2,152.8% upside
Current
$0.68
$0.68
Target
$15.22
$15.22
$10.64
$15.22 avg
$24.41
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 173.28M | 180.17M | 139.91M |
| Net Income | 5.24M | 5.71M | 4.80M |
| Profit Margin | 3.0% | 3.2% | 3.4% |
| EBITDA | 9.18M | 9.37M | 7.10M |
| Free Cash Flow | 6.14M | 5.00M | 3.87M |
| Rev Growth | +9.0% | +21.8% | +16.2% |
| Debt/Equity | 0.62 | 0.48 | 0.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |